Evidence map›Paper›PMID 42517568›Full record

ReviewThe European journal of neuroscience2026

Antibody-Mediated Mechanisms in Autoimmune Neurological Disorders.

Estibaliz Maudes, Laura Marmolejo, Ana Beatriz Serafim, Marianna Spatola, Albert Compte, Josep Dalmau

Abstract readReview
In one paragraph

Review in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antibody-Mediated Mechanisms in Autoimmune Neurological Disorders.The European journal of neuroscience · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Estibaliz MaudesDepartment of Neurology, University Medical Centre, Göttingen, Germany.ORCID 0000-0003-1723-042X
Laura MarmolejoFundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.
Ana Beatriz SerafimFundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.
Marianna SpatolaFundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.
Albert CompteFundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.
Josep DalmauFundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona, Spain.

Funding

Commission for Cultural, Educational and Scientific ExchangeEuropean Committee for Treatment and Research in Multiple SclerosisSpanish National Health Institute Carlos III Spain FI24/00021
6 · The paper itself

Abstract

Antibody-mediated encephalitides are a rapidly evolving class of disorders in which autoantibodies against neuronal surface proteins disrupt synaptic function, neural circuits and cognition. This article summarizes the presentations and discussions from a symposium at the 2025 meeting of the Spanish Society of Neuroscience (SENC). Rather than providing a comprehensive review of autoimmune encephalitis, we highlight selected advances that illustrate how antibody-mediated mechanisms contribute to neurological dysfunction, using anti-NMDAR encephalitis as a paradigmatic example. Specifically, we contrast experimental approaches that have shaped current understanding of disease pathogenesis, including in vitro systems, passive-transfer mouse models and active immunization paradigms that capture B-cell responses, intrathecal immunity, microglial engagement and relapse biology. We also examine emerging evidence that antibody Fc features, including subclass and glycosylation, contribute to innate immune activation and clinical heterogeneity, with examples linking proinflammatory Fc signatures to poorer outcomes. Finally, we review selected studies addressing behavioural and cognitive consequences in animal models and patients, particularly long-lasting deficits in working memory, and discuss therapeutic implications ranging from synapse-stabilizing strategies and NMDAR positive allosteric modulators to B-cell-targeting treatments and approaches aimed at modulating Fc-dependent pathways. Together, these findings suggest that integrating molecular immunoprofiling with systems neuroscience may improve prognostic accuracy and inform therapies that restore immune homeostasis and functional circuit recovery.

Indexed as

AutoantibodiesAutoimmune Diseases of the Nervous SystemEncephalitisHashimoto DiseaseAnimalsHumansReceptors, N-Methyl-D-AspartateAutoantibodiesReceptors, N-Methyl-D-Aspartateanti‐NMDAR encephalitisautoimmune encephalitiscognitive disfunctionneuroimmunologysynaptic plasticity

Identifiers

PMID42517568
PMCPMC13411187

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.